Aptevo Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $3.1M | $12.3M |
| Research and development | $14.5M | $14.4M | $17.1M | $17.9M | $19.0M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M |
| Pretax income | -$26.0M | -$24.1M | -$18.6M | $7.0M | -$29.4M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M | -$28.5M |
| Balance Sheet | |||||
| Cash and equivalents | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M |
| Current assets | $23.1M | $10.7M | $19.1M | $27.4M | $52.6M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M |
| Current liabilities | $6.0M | $6.2M | $7.2M | $8.7M | $34.8M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M |
| Stockholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M |
| Depreciation and amortization | $240,000 | $352,000 | $567,000 | $901,000 | $1.1M |
| Stock-based compensation | $96,000 | $1.1M | $2.2M | $1.8M | $1.6M |
| Capital expenditure | — | — | — | $29,000 | $713,000 |
| Free cash flow | — | — | — | -$21.1M | -$22.4M |
Shares outstanding 1.2M · Free float 98.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.